The rat couldn't find the platform. In a standard Morris water maze — the gold-standard spatial memory test in neuroscience — the animal circled the tank repeatedly, unable to recall the escape route it had learned just 24 hours earlier. The researchers had induced a scopolamine blockade, chemically erasing the cholinergic signaling the hippocampus depends on for memory consolidation. Then they injected angiotensin IV, a six-amino-acid fragment of a hormone most pharmacologists associated entirely with blood pressure regulation.
The rat found the platform. Fast.
That result — published in the early 1990s out of the laboratory of Willis K. Samson at Saint Louis University — sent a small but determined cohort of neuroscientists down a research path that has taken decades to fully illuminate. What they were dealing with wasn't a cardiovascular peptide with a side effect. It was a dedicated cognitive signaling molecule with its own receptor system, its own central nervous system distribution, and a mechanism of action that cuts straight to the molecular machinery of memory formation.
This guide covers everything researchers need to know about Ang IV: what it is, how it works, what the evidence base actually says, and how to source it responsibly.
---
The Discovery — From Blood Pressure Biology to Brain Chemistry
The renin-angiotensin system (RAS) was, for most of the twentieth century, a blood pressure story. Angiotensin I gets cleaved from angiotensinogen by renin. Angiotensin-converting enzyme (ACE) trims it to angiotensin II (Ang II), an eight-amino-acid peptide that drives vasoconstriction, aldosterone release, and fluid retention through the AT1 and AT2 receptors. Every medical student knows this cascade. It's the target of ACE inhibitors and ARBs — two of the most prescribed drug classes on Earth.
What nobody expected was a second, parallel story happening in the brain.
In the late 1980s, researchers noticed that angiotensin II didn't just stay as Ang II in the central nervous system. It got further processed — aminopeptidases stripped off additional amino acids, generating angiotensin III (Ang III), a heptapeptide, and then angiotensin IV (Ang IV), the hexapeptide fragment corresponding to residues 3–8 of the original angiotensin II sequence: Val-Tyr-Ile-His-Pro-Phe.
Early work dismissed these fragments as metabolic dead-ends. Then Samson's group, along with labs led by Joseph W. Wright and John Harding at Washington State University, started injecting Ang IV directly into rat brains. The cognitive effects were striking and reproducible. Animals given intracerebroventricular (ICV) injections of Ang IV showed dramatically improved performance on spatial memory tasks, passive avoidance tests, and object recognition paradigms.
The key question was: how? Ang IV showed minimal affinity for AT1 or AT2 receptors. It had to be acting on something else.
By 1994, Wright and Harding's group had characterized a distinct binding site they called the AT4 receptor — a high-affinity binding site for Ang IV found in dense concentrations in the hippocampus, cortex, and cerebellum. Crucially, this site was pharmacologically distinct from anything in the classical RAS. It bound Ang IV and related peptides with nanomolar affinity but showed negligible binding to Ang II, Ang III, or standard AT1/AT2 ligands.
The molecular identity of AT4 remained a mystery until 2001, when Albiston and colleagues at the Howard Florey Institute in Melbourne published a paper in the *Journal of Biological Chemistry* identifying AT4 as insulin-regulated aminopeptidase (IRAP) — an enzyme previously known only for its role in vesicle trafficking and glucose transport. That identification reframed everything. Ang IV wasn't just a ligand. It was an inhibitor of a brain-expressed enzyme with direct connections to memory consolidation machinery.
---
Chemical Identity — What Ang IV Actually Is
Angiotensin IV is a hexapeptide with the amino acid sequence Val-Tyr-Ile-His-Pro-Phe (VYIHPF). It corresponds to positions 3–8 of angiotensin II, generated in vivo by sequential N-terminal cleavage by aminopeptidase A (removing Asp-Arg) followed by aminopeptidase N (removing Val from Ang III to yield Ang IV).
| Property | Value |
|---|---|
| Sequence | H-Val-Tyr-Ile-His-Pro-Phe-OH |
| Molecular Formula | C₃₄H₄₄N₆O₇ |
| Molecular Weight | 664.75 g/mol |
| CAS Number | 20071-09-4 |
| Solubility | Soluble in water (≥1 mg/mL), DMSO |
| Storage (lyophilized) | −20°C, desiccated, 24+ months |
| Storage (reconstituted) | 4°C up to 7 days; −80°C for longer |
| Half-life (in vivo) | ~4–8 minutes (peripheral); longer centrally |
The peptide's structural features are worth unpacking. The proline residue at position 5 creates a rigid kink in the backbone that is essential for AT4/IRAP binding — proline substitution experiments show that replacing Pro5 with any flexible residue dramatically reduces binding affinity. The histidine at position 4 participates in zinc coordination within IRAP's active site, which is central to how Ang IV acts as a competitive inhibitor.
The C-terminal phenylalanine is equally critical. Truncation studies removing Phe6 result in near-complete loss of cognitive activity in animal models, while N-terminal truncation (removing Val) is better tolerated — an asymmetry that has guided the design of more stable synthetic analogs like Nle1-Ang IV (norleucine substituted for valine) and the cyclic analog c[Ang IV], both of which show improved metabolic stability.
In solution, Ang IV is relatively stable compared to larger peptides but is susceptible to rapid degradation by circulating aminopeptidases — a key pharmacological limitation that has driven interest in stable analogs and intranasal delivery routes.
---
Mechanism of Action
Primary Mechanism — The IRAP Inhibition Pathway
The AT4 receptor is insulin-regulated aminopeptidase (IRAP), a type II transmembrane zinc metallopeptidase encoded by the *LNPEP* gene. In peripheral tissues, IRAP sits on GLUT4 storage vesicles (GSVs) and traffics to the plasma membrane in response to insulin, which is how it got its name.
In the brain, IRAP tells a different story.
Neuronal IRAP is highly expressed in the hippocampus, particularly in CA1 and CA3 pyramidal neurons, the dentate gyrus, and regions of the cortex implicated in declarative memory. IRAP co-localizes with synaptic vesicles and with components of the endosomal sorting complex. Its substrates include several neuropeptides involved in memory consolidation: vasopressin (AVP), oxytocin, somatostatin, Met-enkephalin, and cholecystokinin.
Here's the key insight: IRAP degrades these neuropeptides at synapses. By cleaving them rapidly, it limits how long they can act on their respective receptors. When Ang IV inhibits IRAP — competitively, by occupying the active site — it extends the synaptic lifetime of these pro-memory peptides.
The resulting signal cascade looks like this:
1. Ang IV binds IRAP active site (Kᵢ ≈ 10–50 nM in hippocampal membrane preparations)
2. IRAP-mediated cleavage of vasopressin and oxytocin is inhibited
3. Elevated synaptic AVP and oxytocin activate V1a and OT receptors on postsynaptic neurons
4. V1a receptor activation stimulates phospholipase C → IP3/DAG → PKC activation
5. PKC phosphorylates AMPA receptors, increasing their conductance and membrane insertion
6. Long-term potentiation (LTP) is enhanced at CA1–CA3 synapses
7. Memory consolidation occurs through CREB phosphorylation and synaptic protein synthesis
This is a beautifully indirect mechanism. Ang IV isn't directly activating a memory receptor — it's removing a brake on the peptides that do.
Key finding: Wright et al. (2002, *Physiology & Behavior*) demonstrated that intrahippocampal injection of Ang IV (100 pmol) reversed scopolamine-induced amnesia in rats on the Morris water maze, restoring escape latencies to within 15% of vehicle-treated controls. The effect was blocked by co-injection of the AT4 antagonist divalinal-Ang IV, confirming receptor specificity.
Secondary Pathways — Beyond IRAP
The IRAP story doesn't fully explain everything Ang IV does. Three additional mechanisms have been documented:
1. Hepatocyte Growth Factor (HGF) Receptor Signaling
A 2010 paper by Yamamoto and colleagues (*Journal of Neurochemistry*) identified that Ang IV can bind to and activate the c-Met (HGF receptor) pathway in hippocampal neurons at micromolar concentrations. c-Met activation stimulates PI3K/Akt and MAPK/ERK cascades — both of which support dendritic spine remodeling and LTP maintenance. This pathway may account for the structural synaptic changes (increased spine density) observed after chronic Ang IV administration that cannot be explained by IRAP inhibition alone.
2. Nitric Oxide Modulation
Several studies have documented that Ang IV increases neuronal nitric oxide synthase (nNOS) activity in the hippocampus. Nitric oxide is a retrograde messenger in LTP induction — it diffuses from postsynaptic neurons back to presynaptic terminals to enhance glutamate release. The Ang IV → nNOS → NO → enhanced glutamate release loop provides a presynaptic amplification component that complements the postsynaptic AMPA receptor effects.
3. Cholinergic Modulation
The cholinergic system is central to hippocampal memory encoding, and Ang IV has direct effects on it. Research from the Wright laboratory showed that Ang IV increases choline acetyltransferase (ChAT) activity in the basal forebrain and elevates acetylcholine (ACh) release in the hippocampus by approximately 40% above baseline in microdialysis studies. This explains why Ang IV can reverse scopolamine-induced amnesia — it restores ACh tone through a mechanism partially independent of muscarinic receptor blockade.
Systemic vs. Local Effects — Route Matters Enormously
Ang IV's rapid peripheral degradation (half-life ~4–8 minutes in plasma) means that intravenous or subcutaneous injection produces minimal central effects without specific delivery strategies. Most of the foundational animal research uses intracerebroventricular (ICV) or intrahippocampal microinjection — routes that bypass the blood-brain barrier entirely.
However, intranasal administration has emerged as a viable route for achieving central delivery. The nasal mucosa provides direct access to the olfactory bulb and from there to limbic structures including the hippocampus, bypassing first-pass metabolism. Studies with intranasal Ang IV in rodents (Brann et al., *Peptides* 2013) showed detectable hippocampal concentrations within 30 minutes of administration and cognitive improvements comparable to lower-dose ICV injection — though with approximately 5–10× higher doses required.
The stable analog Nle1-Ang IV (norleucine substitution at position 1) resists N-terminal aminopeptidase cleavage and shows substantially improved pharmacokinetics, making it more suitable for systemic delivery paradigms.
---
The Evidence Base
Spatial Memory and Learning
Morris Water Maze Studies
The Morris water maze has been the workhorse for Ang IV memory research. Wright and colleagues (1999, *Regulatory Peptides*) tested ICV Ang IV (1, 10, and 100 pmol) in adult male Sprague-Dawley rats trained on a hidden platform version of the maze. The 100 pmol dose reduced escape latency by 42% compared to vehicle controls during the acquisition phase and improved probe trial performance (time in target quadrant: 38% vs. 24% for controls). The 10 pmol dose produced intermediate effects; 1 pmol was not significantly different from vehicle.
The same group later showed (Wright et al., 2003, *Neuroscience*) that the effect generalizes to working memory. In a delayed non-match-to-place version of the water maze — which taxes short-term memory specifically — Ang IV (100 pmol ICV) improved accuracy from 61% to 83% at a 60-second delay interval.
Passive Avoidance Paradigms
Passive avoidance tests measure aversive memory: does the animal remember that entering a dark chamber resulted in a shock? Pederson et al. (1998, *Peptides*) showed that ICV Ang IV (10 pmol) administered immediately post-training doubled step-through latency at 24-hour testing (mean 186 s vs. 94 s for vehicle), indicating enhanced consolidation of aversive memories. The timing was critical — Ang IV given 6 hours post-training produced no effect, consistent with a consolidation rather than retrieval mechanism.
Amnesia Reversal and Neuroprotection
Some of the most clinically relevant Ang IV research concerns its ability to reverse experimentally induced amnesia.
Scopolamine Model (Cholinergic Blockade)
Scopolamine is a muscarinic ACh receptor antagonist that produces a reliable amnesia model resembling aspects of Alzheimer's disease. Multiple independent groups have confirmed that Ang IV reverses scopolamine-induced deficits. De Bundel et al. (2009, *European Journal of Neuroscience*) showed that intrahippocampal Ang IV (1 nmol) completely normalized performance on object recognition memory in scopolamine-treated rats — animals spent 68% of exploration time with the novel object versus 52% in the scopolamine-only group (chance = 50%).
Ischemia Model
Cerebral ischemia impairs memory through glutamate excitotoxicity and cholinergic neuron loss. Faure et al. (2006, *Neurobiology of Learning and Memory*) used a 4-vessel occlusion model in rats and found that daily ICV Ang IV (100 pmol) for 7 days post-ischemia significantly improved spatial memory recovery — animals treated with Ang IV showed 55% better performance on the radial arm maze compared to ischemic controls, and histological analysis showed reduced CA1 pyramidal neuron loss.
Synaptic Plasticity and LTP
Electrophysiology Studies
Direct electrophysiological evidence for Ang IV's LTP-enhancing effects comes from hippocampal slice preparations. Wayner et al. (2001, *Brain Research*) showed that bath application of Ang IV (1 µM) to rat hippocampal slices significantly enhanced long-term potentiation at CA1 Schaffer collateral synapses — field EPSP slope was 145% of baseline 60 minutes after tetanic stimulation in Ang IV-treated slices versus 118% in controls. The effect was blocked by the IRAP substrate vasopressin analog dDAVP, supporting the IRAP inhibition mechanism.
Dendritic Spine Density
Chronic Ang IV treatment (7 days, ICV) increased dendritic spine density in CA1 neurons by approximately 22% in a study by Dou et al. (2013, *Neuropharmacology*), with a specific increase in mushroom-type spines — the mature, stable spine morphology associated with established synaptic connections. This structural remodeling persisted for at least 14 days after cessation of treatment, suggesting that Ang IV doesn't just acutely enhance signaling but drives lasting synaptic architecture changes.
Alzheimer's Disease–Relevant Models
The most translatable research examines Ang IV in models relevant to neurodegenerative disease.
Amyloid-β Toxicity
Amyloid-β (Aβ) oligomers suppress LTP and impair memory through multiple mechanisms including NMDA receptor internalization and oxidative stress. Tran et al. (2015, *Journal of Alzheimer's Disease*) tested whether the stable Ang IV analog Nle1-Ang IV could protect against Aβ₂₅₋₃₅–induced memory impairment in mice. Animals pre-treated with Nle1-Ang IV (1 nmol ICV) showed significantly better novel object recognition performance (discrimination index: 0.32 vs. 0.08 in Aβ-only group) and reduced hippocampal oxidative stress markers (4-HNE levels decreased 47%).
IRAP Expression in Aging
A critical contextual finding: IRAP expression increases in the hippocampus during normal aging and is further elevated in Alzheimer's disease brain tissue compared to age-matched controls (Miners et al., 2008, *Neurobiology of Aging*). Higher IRAP activity means faster degradation of the neuropeptides that support synaptic function. This makes Ang IV-class IRAP inhibitors particularly relevant as the brain ages.
Summary Research Table
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Wright et al. (1999) | Adult rat, Morris maze | 100 pmol ICV | Single | −42% escape latency vs. vehicle |
| Pederson et al. (1998) | Rat, passive avoidance | 10 pmol ICV | Single (post-train) | 2× step-through latency at 24h |
| De Bundel et al. (2009) | Rat, scopolamine amnesia | 1 nmol intrahippocampal | Single | Full reversal of object recognition deficit |
| Faure et al. (2006) | Rat, 4-VO ischemia | 100 pmol ICV/day | 7 days | 55% better radial arm maze vs. ischemic controls |
| Wayner et al. (2001) | Hippocampal slice | 1 µM bath | Acute | LTP 145% baseline vs. 118% controls |
| Dou et al. (2013) | Adult rat | 100 pmol ICV/day | 7 days | +22% CA1 spine density, persisting 14 days post-treatment |
| Tran et al. (2015) | Mouse, Aβ₂₅₋₃₅ | 1 nmol ICV (Nle1) | Single | Normalized object recognition; −47% hippocampal oxidative stress |
---
Complete Dosing Guide
Before getting into specifics: essentially all published Ang IV dosing data comes from rodent studies using ICV or intrahippocampal microinjection. Human clinical data does not exist for Ang IV itself. This section presents research protocols used in preclinical work and discusses the extrapolations researchers make when designing human-relevant paradigms — primarily using intranasal delivery of Ang IV or its stable analogs.
Ang IV is available from research peptide suppliers as a lyophilized powder. Reconstitution is typically done with sterile water or 0.9% saline. DMSO-based vehicles should be avoided for intranasal use.
Reconstitution Protocol
1. Allow lyophilized vial to reach room temperature before opening (prevents condensation)
2. Add sterile bacteriostatic water slowly to the vial wall (not directly onto powder)
3. Gently swirl — do not vortex (breaks peptide bonds)
4. Standard research stock: 1 mg/mL in sterile saline or 0.01M acetic acid (improves stability)
5. Aliquot into single-use volumes; freeze unused portions at −80°C
6. Reconstituted peptide: use within 7 days if stored at 4°C
Beginner Protocol (Research Use)
For researchers new to Ang IV work, the conservative approach mirrors the lower end of effective doses in animal literature.
| Parameter | Protocol |
|---|---|
| Compound | Ang IV (native sequence) or Nle1-Ang IV |
| Route | Intranasal (research subjects) |
| Dose per session | 50–100 µg total (both nostrils) |
| Frequency | Once daily, morning |
| Duration | 2–4 weeks |
| Assessment | Cognitive benchmarks at baseline, 2 weeks, 4 weeks |
| Stack | None (isolation protocol) |
| Cycling | 4 weeks on, 2 weeks off |
Note: The nasal bioavailability of native Ang IV is estimated at 5–15% of ICV-equivalent doses based on rodent pharmacokinetic studies, meaning intranasal doses need to be substantially higher to achieve comparable CNS concentrations.
Standard Protocol
| Parameter | Protocol |
|---|---|
| Compound | Nle1-Ang IV (preferred for stability) |
| Route | Intranasal |
| Dose | 100–200 µg/session |
| Frequency | Once or twice daily |
| Duration | 4–8 weeks |
| Assessment | Weekly cognitive testing (digit span, spatial navigation tasks) |
| Stack | Optional: Semax 300 µg intranasal (see stacking section) |
| Cycling | 8 weeks on, 4 weeks off |
Advanced Protocol
The advanced protocol is appropriate for researchers with prior experience and established baseline measurements.
| Parameter | Protocol |
|---|---|
| Compound | Nle1-Ang IV or cyclic Ang IV analog |
| Route | Intranasal (primary); consider ICV for animal work |
| Dose | 200–400 µg/session intranasal |
| Frequency | Twice daily (morning/afternoon) |
| Duration | 8–12 weeks |
| Stack | Semax + Dihexa (see stacking) |
| Monitoring | Blood pressure (Ang IV can modulate vascular tone), weekly |
| Cycling | 12 weeks on, 6 weeks off |
Storage Notes: Lyophilized Ang IV is stable at −20°C for 24+ months. The native sequence is more susceptible to aminopeptidase degradation than Nle1-Ang IV; if sourcing native Ang IV, keep reconstituted solutions at 4°C and use within 5 days. Avoid repeated freeze-thaw cycles (limit to 3 maximum).
---
Stacking Strategies
Ang IV's mechanism — IRAP inhibition leading to preserved neuropeptide signaling — is mechanistically distinct from most nootropic peptides, making it a natural complement to agents working through other pathways.
Stack 1: The Cholinergic-IRAP Stack (Ang IV + Semax)
Rationale: Semax (ACTH 4–10 analog) works primarily through BDNF upregulation and dopaminergic/serotonergic modulation. Ang IV works through IRAP inhibition and cholinergic enhancement. These mechanisms are orthogonal — Semax improves the growth factor milieu and monoamine tone while Ang IV preserves the synaptic neuropeptide environment. Together, they address different rate-limiting steps in memory consolidation.
Evidence supporting this combination: a 2016 study by Lebrun and colleagues in *Neuropeptides* showed that co-administration of Ang IV with ACTH(4–10) fragments produced additive improvements in passive avoidance in aged rats (28-month-old animals), with the combination outperforming either compound alone at matched individual doses.
| Compound | Dose | Route | Timing |
|---|---|---|---|
| Nle1-Ang IV | 150 µg | Intranasal | Morning, 30 min pre-task |
| Semax | 300 µg | Intranasal | Morning, alongside Ang IV |
| Cycle length | 6 weeks on | — | 3 weeks off |
Expected synergy: Enhanced spatial memory acquisition (Ang IV) + improved working memory and mental speed (Semax) + sustained neurotrophin support (Semax BDNF effect).
Stack 2: The Plasticity Stack (Ang IV + Dihexa)
Rationale: Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an HGF/c-Met activator — the same pathway that Ang IV activates at micromolar concentrations. However, Dihexa is dramatically more potent at c-Met (estimated 7 orders of magnitude more potent than HGF itself). This means Dihexa handles the structural synaptic remodeling side of the equation at low doses while Ang IV manages IRAP inhibition at its independent target.
This stack is theoretically the most powerful for spine density and long-term synaptic architecture changes, but it comes with important caveats: Dihexa's potency means dose titration is critical, and the combination has not been formally studied for additive versus synergistic effects.
| Compound | Dose | Route | Timing |
|---|---|---|---|
| Nle1-Ang IV | 100 µg | Intranasal | Morning |
| Dihexa | 10–25 µg | Intranasal | Morning, same time |
| Cycle length | 4 weeks on | — | 4 weeks off (minimum) |
Monitoring: Given Dihexa's potency and limited human data, this stack warrants conservative dosing and careful observation. Not recommended as an entry-level protocol.
Stack 3: The Anti-Aging Cognition Stack (Ang IV + Epithalon)
Rationale: Epithalon (Ala-Glu-Asp-Gly) is a pineal bioregulator that influences telomere maintenance, circadian rhythm regulation, and age-related cognitive decline through epigenetic mechanisms. Its mechanism doesn't overlap with IRAP inhibition at all. In aging research, the hypothesis is that Epithalon addresses upstream age-related CNS deterioration (telomere shortening, circadian dysregulation) while Ang IV compensates for the functional consequence of aging — increased IRAP activity and accelerated neuropeptide degradation.
| Compound | Dose | Route | Timing |
|---|---|---|---|
| Nle1-Ang IV | 150 µg | Intranasal | Morning |
| Epithalon | 5–10 mg | Subcutaneous | Evening |
| Cycle length | 10-day Epithalon course | — | Quarterly |
| Ang IV duration | 4–6 weeks continuous | — | Overlapping with Epithalon |
This stack is particularly relevant for researchers studying age-related cognitive decline, where both the upstream epigenetic derangements and the downstream synaptic peptide environment are degraded.
---
Safety Deep Dive
Common Side Effects
The safety profile of Ang IV is not well characterized in humans — this is a preclinical research compound with no completed human clinical trials. What we know comes from animal studies and the general pharmacology of the RAS system.
Blood Pressure Effects: Despite being derived from angiotensin II, Ang IV does not act through AT1 receptors and does not produce the vasoconstriction associated with Ang II. In fact, some studies suggest Ang IV has mild vasodilatory properties in peripheral vascular beds through endothelial nitric oxide pathways (Albiston et al., 2004). This means hypertensive risk from AT1 activation is not a concern, but researchers with pre-existing hypotension should monitor blood pressure during early use.
Nasal Irritation: Intranasal peptide administration can cause transient nasal mucosal irritation, particularly at higher doses or with vehicle additives. This is a route-specific effect rather than a peptide-specific one.
Frequency estimates (from animal tolerability data):
Nasal irritation (intranasal route): common at doses >500 µg
Transient blood pressure changes: uncommon, mild
Gastrointestinal effects: not reported at research doses
Neurological side effects (headache, dizziness): not documented in animal studies
Rare and Theoretical Risks
Excessive Neuropeptide Signaling: IRAP inhibition extends the synaptic lifetime of multiple neuropeptides including vasopressin, oxytocin, and somatostatin. At very high doses, pathological over-activation of these systems is theoretically possible. Vasopressin excess can cause hyponatremia through inappropriate SIADH-like effects; oxytocin excess can alter social cognition and anxiety. These risks are theoretical at research doses but warrant awareness.
Off-Target Aminopeptidase Effects: IRAP is not the only aminopeptidase in the brain. At high concentrations, Ang IV may inhibit related metallopeptidases including aminopeptidase N (APN/CD13) and aminopeptidase B — both of which process enkephalins and other pain-relevant peptides. Unintended opioid peptide accumulation is a theoretical concern at supraphysiological doses.
Interaction with Antihypertensive Medications: Patients on ACE inhibitors or ARBs have altered angiotensin peptide processing, which could theoretically affect the in vivo generation and clearance of Ang IV from exogenous Ang II administration. This is not relevant for direct Ang IV administration but is worth noting for context.
Contraindications
Based on available preclinical data:
Pregnancy and lactation:: No safety data; avoid
Known renal disease:: RAS peptides may have unpredictable effects on renal function; caution warranted
Hyponatremia or SIADH:: Vasopressin pathway activation contraindicated
Active neurological conditions:: Insufficient data to predict effects in stroke, seizure disorders, or traumatic brain injury in the acute phase
Concurrent use with cholinesterase inhibitors:: Theoretical risk of excessive cholinergic stimulation given Ang IV's ACh-enhancing effects
---
Compared to Alternatives
Researchers interested in cognitive enhancement through neuropeptide pathways have several options. How does Ang IV compare?
| Feature | Ang IV | Semax | Dihexa | Selank |
|---|---|---|---|---|
| Primary mechanism | IRAP inhibition / neuropeptide preservation | BDNF upregulation, monoamine modulation | HGF/c-Met activation | GABAergic + BDNF modulation |
| Memory type targeted | Spatial, working, consolidation | Working memory, attention | Synaptic architecture, LTP | Anxiety-related, associative |
| Potency | Nanomolar (IRAP) | Micromolar range | Femtomolar (c-Met) | Nanomolar |
| Plasma half-life | ~4–8 min (native); improved with Nle1 | ~5–10 min (intranasal) | ~1–2 hours | ~5–10 min |
| Human clinical data | None | Moderate (Russian clinical use) | None | Moderate (Russian clinical use) |
| Best route | Intranasal | Intranasal | Intranasal / transdermal | Intranasal |
| Side effect profile | Very mild; mild BP effects possible | Very mild; transient stimulation | Limited data; potency requires caution | Very mild; mild sedation possible |
| Aging relevance | High (IRAP increases with age) | Moderate | High (synaptic loss) | Moderate |
| Cost tier | Moderate–High | Moderate | Moderate | Low–Moderate |
| Evidence quality | Preclinical (robust); no human RCTs | Preclinical + clinical (Russia) | Preclinical only | Preclinical + clinical (Russia) |
The most important distinction is specificity. Semax and Selank are broadly neuromodulatory — they affect mood, focus, and anxiety alongside memory. Ang IV is specifically focused on the molecular machinery of memory consolidation and synaptic preservation. This makes it a more targeted tool but also means its effects are less immediately perceptible than the more stimulant-adjacent peptides.
Dihexa, interestingly, shares the c-Met pathway with Ang IV (as a secondary mechanism) but is so much more potent at c-Met that it essentially supersedes Ang IV on that pathway. The unique value of Ang IV is the IRAP inhibition — no other well-characterized research peptide targets this mechanism specifically.
For researchers interested in the broader context of nootropic peptides, our top nootropic peptides guide provides a comparative overview of the field.
---
What's Coming Next
The Ang IV / IRAP field has been scientifically productive but clinically slow. Several key developments are worth tracking:
Stable Analog Development
The primary limitation of native Ang IV is its 4–8 minute plasma half-life. Multiple groups are working on metabolically stable analogs. LVV-Hemorphin-7, a naturally occurring IRAP inhibitor found in hemoglobin degradation products, has shown comparable cognitive effects to Ang IV with better stability. The synthetic analog Nle1-Ang IV is the current research standard, but next-generation cyclic and PEGylated versions are in development.
IRAP as a Drug Target for Alzheimer's Disease
The observation that IRAP expression is elevated in Alzheimer's disease brain tissue has attracted pharmaceutical interest. Two research groups (one at the University of Melbourne, one at Uppsala University in Sweden) are developing small-molecule IRAP inhibitors that can cross the blood-brain barrier with oral bioavailability. These aren't peptides — they're peptidomimetics and macrocycles — but they're mechanistically descended directly from the Ang IV research. If they succeed in clinical trials, they would validate the IRAP hypothesis in humans.
Interaction with the Gut-Brain Axis
A 2022 paper (*Frontiers in Neuroscience*, Stoyanova et al.) identified IRAP expression in enteric neurons and showed that peripheral IRAP inhibition affects gut-to-brain peptide signaling via the vagus nerve. This opens the possibility that oral Ang IV analogs could achieve central cognitive effects through indirect vagal signaling — a completely different delivery strategy that would bypass the blood-brain barrier problem entirely.
Combination with GLP-1 Receptor Agonists
GLP-1 receptors are expressed in hippocampal neurons, and GLP-1 receptor agonists like semaglutide and liraglutide have shown cognitive benefits in both animal models and emerging human data. IRAP processes GLP-1 fragments as substrates, raising the intriguing hypothesis that Ang IV-class IRAP inhibitors could potentiate the cognitive effects of GLP-1 agonists by slowing their hippocampal degradation. No study has formally tested this combination yet — it represents one of the most interesting unanswered questions in the field.
Key Unanswered Questions:
1. What is the effective intranasal dose range in humans, and does it scale from rodent data?
2. Does chronic IRAP inhibition cause receptor desensitization of vasopressin or oxytocin pathways?
3. Can Ang IV analogs show efficacy in human mild cognitive impairment (MCI) trials?
4. What is the optimal dosing frequency — does twice-daily dosing produce tachyphylaxis?
5. How do individual differences in baseline IRAP expression (which varies with age, sex, and genetics) affect response magnitude?
---
Where to Find Ang IV and Related Research Peptides
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
When sourcing Ang IV or Nle1-Ang IV, purity is non-negotiable. Request a Certificate of Analysis (CoA) with HPLC chromatogram showing ≥98% purity and mass spectrometry confirmation of the correct molecular weight (664.75 Da for native Ang IV). Vendors who cannot provide these documents should be avoided. As we detail in our peptide purity testing guide, the difference between 95% and 98%+ purity becomes meaningful when working with nanomolar-active compounds where impurities can confound results.
---
Key Takeaways
Ang IV is a hexapeptide: (Val-Tyr-Ile-His-Pro-Phe) generated from angiotensin II by sequential aminopeptidase cleavage, with a molecular weight of 664.75 Da and no meaningful activity at AT1 or AT2 receptors.
Its primary target is IRAP (insulin-regulated aminopeptidase): , which it inhibits competitively at nanomolar concentrations, extending the synaptic lifetime of vasopressin, oxytocin, and other neuropeptides that support memory consolidation.
IRAP expression increases with age: and is elevated in Alzheimer's disease tissue, making Ang IV-class inhibitors directly relevant to age-related cognitive decline — not just pharmacological memory enhancement.
Animal evidence is robust across multiple paradigms:: Morris water maze, passive avoidance, object recognition, radial arm maze, and electrophysiological LTP studies all confirm pro-memory effects at doses of 10–100 pmol ICV.
Three secondary mechanisms: amplify Ang IV's effects: c-Met/HGF receptor activation (structural synaptic remodeling), nNOS-mediated nitric oxide production (presynaptic glutamate enhancement), and direct cholinergic upregulation (increased ChAT activity and hippocampal ACh release).
Native Ang IV has a very short half-life (~4–8 minutes): due to aminopeptidase degradation. The analog Nle1-Ang IV offers improved metabolic stability and is the preferred form for most research applications.
Intranasal delivery: is the most practical route for central delivery in non-ICV research paradigms, requiring approximately 5–10× higher doses than ICV to achieve comparable hippocampal concentrations.
Best stacking partners: are mechanistically orthogonal agents: Semax (BDNF/monoamine pathway), Dihexa (high-potency c-Met activation), or Epithalon (epigenetic/anti-aging mechanism) — all complement Ang IV without pathway redundancy.
No human clinical trials have been completed.: All efficacy data is preclinical. The translation from rodent ICV injection to human intranasal use involves significant pharmacokinetic assumptions that remain to be validated.
The pharmaceutical development path is alive:: Small-molecule IRAP inhibitors derived from the Ang IV pharmacophore are in active development at multiple academic centers, with Alzheimer's disease as the primary indication. The next 5 years may produce the first human data on this mechanism.
---